Business Description
Abbott Laboratories
NAICS : 339112
SIC : 3841
Compare
Compare
Traded in other countries / regions
ABT.USA0Q15.UKABT.PeruABT.MexicoABT.ArgentinaABL.GermanyABTT34.BrazilABT.AustriaABT.ChileABT_KZ.KazakhstanABL.BulgariaABT.Switzerland IPO Date
2022-11-14Description
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.53 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | 1.39 | |||||
| Interest Coverage | 12.21 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6.06 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.1 | |||||
| 3-Year EBITDA Growth Rate | -3.5 | |||||
| 3-Year EPS without NRI Growth Rate | -3.6 | |||||
| 3-Year FCF Growth Rate | -9.1 | |||||
| 3-Year Book Growth Rate | 10.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.58 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.87 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 6-1 Month Momentum % | 13.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | |||||
| Quick Ratio | 1.23 | |||||
| Cash Ratio | 0.56 | |||||
| Days Inventory | 129.63 | |||||
| Days Sales Outstanding | 59.17 | |||||
| Days Payable | 81.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.47 | |||||
| 3-Year Dividend Growth Rate | 6.9 | |||||
| 3-Year Average Share Buyback Ratio | 0.6 | |||||
| Shareholder Yield % | 2.74 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.41 | |||||
| Operating Margin % | 16.27 | |||||
| Net Margin % | 31.95 | |||||
| FCF Margin % | 15.14 | |||||
| ROE % | 32.82 | |||||
| ROA % | 17.89 | |||||
| ROIC % | 23.69 | |||||
| 3-Year ROIIC % | 70.62 | |||||
| ROC (Joel Greenblatt) % | 66.81 | |||||
| ROCE % | 12.46 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.04 | |||||
| Forward PE Ratio | 10.93 | |||||
| PE Ratio without NRI | 29.55 | |||||
| Shiller PE Ratio | 42.48 | |||||
| Price-to-Owner-Earnings | 42.4 | |||||
| PEG Ratio | 4.28 | |||||
| PS Ratio | 5.75 | |||||
| PB Ratio | 5.01 | |||||
| Price-to-Tangible-Book | 13.35 | |||||
| Price-to-Free-Cash-Flow | 37.97 | |||||
| Price-to-Operating-Cash-Flow | 28.18 | |||||
| EV-to-EBIT | 32.57 | |||||
| EV-to-Forward-EBIT | 25.38 | |||||
| EV-to-EBITDA | 22.86 | |||||
| EV-to-Forward-EBITDA | 19.58 | |||||
| EV-to-Revenue | 5.88 | |||||
| EV-to-Forward-Revenue | 5.31 | |||||
| EV-to-FCF | 38.84 | |||||
| Price-to-GF-Value | 1.25 | |||||
| Price-to-Projected-FCF | 2.18 | |||||
| Price-to-DCF (Earnings Based) | 0.66 | |||||
| Price-to-DCF (FCF Based) | 0.88 | |||||
| Price-to-Median-PS-Value | 1.31 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.5 | |||||
| Price-to-Graham-Number | 4.19 | |||||
| Earnings Yield (Greenblatt) % | 3.07 | |||||
| FCF Yield % | 2.65 | |||||
| Forward Rate of Return (Yacktman) % | 9.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abbott Laboratories Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil лв) | 78,354.672 | ||
| EPS (TTM) (лв) | 14.288 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (лв) | 0.00086 | ||
| 20-Day SMA (лв) | 106.12 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (лв) | 93.87 - 106.12 | ||
| Shares Outstanding (Mil) | 1,734.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbott Laboratories Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abbott Laboratories Stock Events
| Event | Date | Price (лв) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abbott Laboratories Frequently Asked Questions
What is Abbott Laboratories(XBUL:ABL)'s stock price today?
The current price of XBUL:ABL is лв106.12. The 52 week high of XBUL:ABL is лв106.12 and 52 week low is лв93.87.
When is next earnings date of Abbott Laboratories(XBUL:ABL)?
The next earnings date of Abbott Laboratories(XBUL:ABL) is 2025-04-17 Est..
Does Abbott Laboratories(XBUL:ABL) pay dividends? If so, how much?
Abbott Laboratories(XBUL:ABL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers